Revenue: $662 million, up 4% reported and 7% in constant currency. Instrument Sales Growth: 11%, driven by mid-teens growth in liquid chromatography and mass spectrometry. Pharma Sales Growth: 8%, with double-digit growth in Asia and the Americas. Industrial Sales Growth: 6%, led by PFAS applications growing over 90%. Academic and Government Sales Growth: 3%, with China growing double digits. Non-GAAP EPS: $2.25, reflecting low single-digit growth and high single-digit growth in constant currency. GAAP EPS: $2.03. Gross Margin: 58.2%. Adjusted Operating Margin: 25.5%. Free Cash Flow: $234 million, representing 35% of first quarter sales. Net Debt: Approximately $1.1 billion, with a net debt-to-EBITDA ratio of roughly 1 time. Full Year 2025 Sales Growth Guidance: Raised to 5% to 7% in constant currency. Full Year 2025 Adjusted EPS Guidance: Raised to $12.75 to $13.05, representing 8% to 10% growth. Second Quarter 2025 Sales Growth Guidance: 5% to 7% in constant currency. Second Quarter 2025 Non-GAAP EPS Guidance: $2.88 to $2.98, representing 10% to 13% reported growth.

Warning! GuruFocus has detected 2 Warning Sign with WAT.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Waters Corp (NYSE:WAT) reported strong double-digit instrument growth, driven by mid-teens sales growth in both liquid chromatography and mass spectrometry. The company achieved a 7% sales growth in constant currency, landing at the high end of their guidance. Waters Corp (NYSE:WAT) raised its full-year constant currency sales growth guidance to 5% to 7% due to better-than-expected first-quarter performance. The company successfully mitigated the impact of newly announced tariffs, limiting the net impact to a modest $10 million on their 2025 adjusted operating margin. Waters Corp (NYSE:WAT) demonstrated strong free cash flow generation, allowing them to rapidly deleverage their balance sheet, reducing debt by approximately $170 million.

Negative Points

The company faces a potential 50 basis point impact on their full-year growth outlook due to adjustments in the US academic and government end market. Despite strong performance, the US academic and government segment is expected to decline by 20% for the rest of the year. Waters Corp (NYSE:WAT) has a $45 million gross exposure to tariffs, primarily affecting the second half of 2025. The company noted continued pressure on biotech, drug discovery, and pharma research segments, which are less than 20% of their overall pharma business. TA Instruments, a division of Waters Corp (NYSE:WAT), experienced lower-than-expected growth, attributed to timing of different orders.

Story Continues

Q & A Highlights

Q: Can you discuss the replacement cycle dynamics in the pharma sector and any updates to the 2025 forecast for instruments? A: Udit Batra, President and CEO, explained that the replacement cycle in pharma is well underway, with strong growth driven by large pharma, generics, and CDMOs. Amol Chaubal, CFO, noted that the only change in the 2025 guide is a proactive derisking of the US academic and government business, which is a small portion of their overall business.

Q: Have you seen any change in behavior from pharma biotech customers related to tariffs? A: Udit Batra stated that there has been no change in customer behavior related to tariffs. The company is well-positioned with large pharma players who are considering reshoring in the US, but this is not included in their guidance.

Q: What are your expectations for pricing this year, and are you concerned about pharma pushing back on pricing? A: Amol Chaubal mentioned that they achieved 200 basis points of like-for-like pricing gains in Q1, with additional surcharges related to tariffs contributing another 50 basis points. Udit Batra added that there has been close collaboration with customers, and most have understood the need for tariff surcharges.

Q: How do you view the potential risks and sustainability of growth in India, especially with manufacturing moves and onshoring? A: Udit Batra emphasized that Indian generics companies have global footprints and are capable of reshoring if necessary. The company has strong relationships with these companies and is ready to help them navigate any changes. India saw close to 20% constant currency growth, driven by innovative products.

Q: What are your expectations for China for the rest of the year, and are you seeing any hesitation in customer spending? A: Udit Batra noted that China grew 5% in Q1, driven by stimulus-related opportunities and battery testing. For the rest of the year, they expect low single-digit growth, with any additional stimulus considered upside.

Q: How do you view reshoring as a potential tailwind, and when do you expect demand to start coming for your products? A: Udit Batra stated that it is early days for reshoring announcements, and they are in close conversation with customers. They expect to play a strong role in supporting existing products, but detailed plans are not yet available.

Q: Can you elaborate on the PFAS business growth and its sustainability? A: Udit Batra highlighted that PFAS testing has grown 40% annually for the past two years and 90% in Q1 2025. The growth is driven by strong demand in food and environmental segments, with continued regulatory focus on PFAS testing.

Q: What is your appetite for acquisitions, and do you expect macro volatility to lead to more attractive valuations? A: Udit Batra expressed interest in acquisitions similar to the successful Wyatt acquisition, which has strengthened their bioanalytical business. They are open to opportunities with reasonable valuations but will also consider resuming share buybacks if strategic fits are not found.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments